Key result
Insertion of CPVT-causing mutations in C. elegans UNC-68 reduced the ability of the pharynx to follow 4 Hz optogenetic stimulation, an arrhythmia-like phenotype that was reversed in a mutation-specific manner by the benzothiazepine S107.
The C. elegans optogenetic model successfully recapitulates CPVT-like arrhythmia phenotypes that can be reversed by S107, providing a high-throughput system for studying RyR mutations and drug screening.
Three RyR mutations induce arrhythmia-like phenotypes reversible by S107; hypothesis-generating for mutation-specific CPVT therapies.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disturbance of the heart rhythm (arrhythmia) that is induced by stress or that occurs during exercise. Most mutations that have been linked to CPVT are found in two genes, i.e., ryanodine receptor 2 (RyR2) and calsequestrin 2 (CASQ2), two proteins fundamentally involved in the regulation of intracellular Ca 2+ in cardiac myocytes. We inserted six CPVT-causing mutations via clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 into unc-68 and csq-1 , the Caenorhabditis elegans homologs of RyR and CASQ, respectively. We characterized those mutations via video-microscopy, electrophysiology, and calcium imaging in our previously established optogenetic arrhythmia model. In this study, we additionally enabled high(er) throughput recordings of intact animals by combining optogenetic stimulation with a microfluidic chip system. Whereas only minor/no pump deficiency of the pharynx was observed at baseline, three mutations of UNC-68 (S2378L, P2460S, Q4623R; RyR2-S2246L, -P2328S, -Q4201R) reduced the ability of the organ to follow 4 Hz optogenetic stimulation. One mutation (Q4623R) was accompanied by a strong reduction of maximal pump rate. In addition, S2378L and Q4623R evoked an altered calcium handling during optogenetic stimulation. The 1,4-benzothiazepine S107, which is suggested to stabilize RyR2 channels by enhancing the binding of calstabin2, reversed the reduction of pumping ability in a mutation-specific fashion. However, this depends on the presence of FKB-2, a C. elegans calstabin2 homolog, indicating the involvement of calstabin2 in the disease-causing mechanisms of the respective mutations. In conclusion, we showed for three CPVT-like mutations in C. elegans RyR a reduced pumping ability upon light stimulation, i.e., an arrhythmia-like phenotype, that can be reversed in two cases by the benzothiazepine S107 and that depends on stabilization via FKB-2. The genetically amenable nematode in combination with optogenetics and high(er) throughput recordings is a promising straightforward system for the investigation of RyR mutations and the selection of mutation-specific drugs.
No takes yet. Share an insight, caveat, or question.
Engel et al. (2022) studied Catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT mutations and S107 treatment vs. Wild-type C. elegans or vehicle was evaluated on Pharyngeal pump rate during 4 Hz optogenetic stimulation. Insertion of CPVT-causing mutations in C. elegans UNC-68 reduced the ability of the pharynx to follow 4 Hz optogenetic stimulation, an arrhythmia-like phenotype that was reversed in a mutation-specific manner by the benzothiazepine S107.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: